European Companies Search Engine
UK funding (£675,339): Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture Ukri1 Dec 2022 UK Research and Innovation, United Kingdom
Overview
Text
Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture
| Abstract | One of the major factors limiting understanding the complex dynamic environment in the gut, is the technical difficulty of accessing or visualising the GI tract. GIBio provides a mechanism to replicate the dynamic environment of the gut without the costs or variability associated with animal or human studies such that the design, development and manufacture of formulated ingested products will be transformed. GIBio underpins the development of robust products by providing clinical quality data early in development to accelerate the translation of healthcare technologies to patients. This gold standard equipment, the only accessible facility in the UK, will reduce the time and costs associated with the design, development and manufacture of new drug products. Oral administration is the most common drug delivery route. Absorption of a drug from the gut into the bloodstream involves disintegration of the dosage form, dissolution of the drug, and transport across the gut wall. The efficiency of these processes is determined by highly complex and dynamic interactions between the gastrointestinal tract, the dosage form and the drug. This complex interplay determines drug delivery performance and may cause large interindividual variability, but is poorly understood. The fine tuning of the equipment to reproduce the gut in health and disease will ensure that patient centric products are developed to improve therapeutic outcomes. Furthermore, GIBio will generate new research opportunities in formulated ingested products from the food, including animal feed industries and in the evaluation of ingested sensors and medical devices. |
| Category | Research Grant |
| Reference | EP/W036452/1 |
| Status | Active |
| Funded period start | 01/12/2022 |
| Funded period end | 31/05/2026 |
| Funded value | £675,339.00 |
| Source | https://gtr.ukri.org/projects?ref=EP%2FW036452%2F1 |
Participating Organisations
| University of Strathclyde | |
| University of Copenhagen | |
| Pfizer Global R & D | |
| Novartis | |
| MERCK | |
| AstraZeneca | |
| AbbVie Inc | |
| National and Kapodistrian University of Athens | |
| Johnson & Johnson | |
| Boehringer Ingelheim | |
| GlaxoSmithKline (GSK) | |
| University of Leuven | |
| TIM BV - The TIM Company | |
| Centre for Process Innovation CPI (UK) | |
| ASTRAZENECA UK LIMITED |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: University of Strathclyde, Glasgow.
The visualizations for "University of Strathclyde - UK funding (£675,339): Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
